Expert Opinion | By Januzzi JL Jr, Mahler SA, Christenson RH et al.
High-sensitivity cardiac troponin (hs-cTn) I or T methods have been in use in certain regions for years but are now increasingly globally adopted, including in the United States. Accordingly, inevitable challenges are created for institutions transitioning from conventional cardiac troponin (cTn) assays. hs-cTn assays have higher analytic precision at lower concentrations, yielding greater clinical sensitivity for myocardial injury and allowin...
Management of No-Reflow Phenomenon in the Catheterization Laboratory
Review Article | By Rezkalla SH, Stankowski RV, Hanna J et al.
Advances in Coronary No-Reflow Phenomenon-a Contemporary Review
Review Article | By Karimianpour A, Maran A.
PURPOSE OF REVIEW - Coronary artery no-reflow phenomenon is an incidental outcome of percutaneous coronary intervention in patients presenting with acute myocardial infarction. Despite advances in pharmacologic and non-pharmacologic therapies, coronary no-reflow phenomenon occurs more commonly than desired. It often results in poor clinical outcomes and remains as a relevant consideration in the cardiac catheterization laborator...
Please click on "Article Link" on the right side to get further access.
Original Research | By Muller O, Windecker S, Cuisset T et al.
The no-reflow phenomenon has been defined in 2001 by Eeckhout and Kern as inadequate myocardial perfusion through a given segment of the coronary circulation without angiographic evidence of mechanical vessel obstruction1. Rates of cardiac death and non-fatal cardiac events are increased in patients with compared to those without no-reflow2,3. The term “no reflow” encompasses the slow-flow, slow-reflow, no-flow and low-fl...
Original Research | By Fournier S, Ciccarelli G, Toth GG et al.
IMPORTANCE - Whether the improvement in myocardial perfusion provided by percutaneous coronary intervention (PCI) is associated with symptomatic relief or improved outcomes has not been well investigated. OBJECTIVE - To investigate the prognostic value of the improvement in fractional flow reserve (FFR) after PCI (ΔFFR) on patients' symptoms and 2-year outcomes. Desig...
Original Research | By Velazquez EJ, Morrow DA, DeVore AD et al.
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Clinical Trial | By Velazquez EJ, Morrow DA, DeVore AD et al.
BACKGROUND - Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown. METHODS - We enrolled patients with heart failure with reduced ejection fraction who were hospitalized for acute decompen...
Original Research | By Turakhia MP, Desai M, Perez MV et al.